Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00240318 · ClinicalTrials.gov registry record · Phase 3
A Study To Evaluate the Effect of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID)
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 450
- Enrollment target
NCT00240318 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 450 participants.
The verdict
NCT00240318, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 450 participants
- Enrollment target
Study Summary
The purpose of this study is to see if 40 mg of rosuvastatin taken daily will reduce the atherosclerosis (fatty deposits) in your arteries
Interventions
- DRUG Rosuvastatin calcium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2002-11 |
| Est. Completion | 2005-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00240318
The ClinicalTrials.gov registry entry for NCT00240318 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rosuvastatin calcium is the first listed.
NCT00240318 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00240318 about?
NCT00240318 is a clinical study titled "A Study To Evaluate the Effect of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID)". The purpose of this study is to see if 40 mg of rosuvastatin taken daily will reduce the atherosclerosis (fatty deposits) in your arteries
What is the current status of trial NCT00240318?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 450 participants. The study started on 2002-11. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00240318?
The interventions under investigation include: Rosuvastatin calcium (DRUG).
Who is sponsoring clinical trial NCT00240318?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.